Carcinoma

• CLINICAL_TRIALS withdrawal · 2025-05-18
  Clinical Trial Update: Study of High Dose Intravenous (IV) Ascorbic Acid in Measurable Solid Tumor Disease [Phase 2]

  A Phase 2 trial evaluating high-dose intravenous ascorbic acid in measurable solid tumors has been withdrawn, sponsored by Situs Cancer Rese…

• CLINICAL_TRIALS withdrawal · 2025-01-01
  Clinical Trial Update: A Pilot Study of Thermodox and MR-HIFU for Treatment of Relapsed Solid Tumors [Phase 2]

  A Phase 2 pilot study evaluating Thermodox in combination with MR-HIFU for relapsed solid tumors has been withdrawn.

• CLINICAL_TRIALS withdrawal · 2020-05-07
  Clinical Trial Update: Efficacy and Safety of UGN-101 in Recurrent Patients [Phase 3]

  Phase 3 trial of UGN-101 for recurrent carcinoma variants has been withdrawn.

• CLINICAL_TRIALS withdrawal · 2017-05-15
  Clinical Trial Update: A Study to Evaluate Corrected QT Interval From Clinical Studies Conducted With Bevacizumab

  This update notes that a study evaluating the corrected QT interval with bevacizumab has been withdrawn.

• CLINICAL_TRIALS withdrawal · 2016-07-13
  Clinical Trial Update: EBUS-TBNA Versus EBUS-TBNB [NA]

  A clinical trial comparing EBUS-TBNA to EBUS-TBNB has been withdrawn from the registry, per the sponsor Royal Brompton & Harefield NHS Found…

• Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
• EMA withdrawal · 2014-11-14
  EMA Withdrawn: Topotecan Eagle (topotecan hydrochloride) — Eagle Laboratories Ltd.

  EMA has withdrawn Topotecan Eagle (topotecan hydrochloride) from the market.